title: Neural substrates of cognitive flexibility in cocaine and gambling addictions.
abstract: BACKGROUND
  Individuals with cocaine and gambling addictions exhibit cognitive flexibility deficits that may underlie persistence of harmful behaviours.
  
  
  OBJECTIVE
  We investigated the neural substrates of cognitive inflexibility in cocaine users v. pathological gamblers, aiming to disambiguate common mechanisms v. cocaine effects.
  
  
  METHODS
  Eighteen cocaine users, 18 pathological gamblers and 18 controls performed a probabilistic reversal learning task during functional magnetic resonance imaging, and were genotyped for the DRD2/ANKK Taq1A polymorphism.
  
  
  RESULTS
  Cocaine users and pathological gamblers exhibited reduced ventrolateral prefrontal cortex (PFC) signal during reversal shifting. Cocaine users further showed increased dorsomedial PFC (dmPFC) activation relative to pathological gamblers during perseveration, and decreased dorsolateral PFC activation relative to pathological gamblers and controls during shifting. Preliminary genetic findings indicated that cocaine users carrying the DRD2/ANKK Taq1A1+ genotype may derive unique stimulatory effects on shifting-related ventrolateral PFC signal.
  
  
  CONCLUSIONS
  Reduced ventrolateral PFC activation during shifting may constitute a common neural marker across gambling and cocaine addictions. Additional cocaine-related effects relate to a wider pattern of task-related dysregulation, reflected in signal abnormalities in dorsolateral and dmPFC.
authors.affiliation: Antonio Verdejo-Garcia, PhD, School of Psychology and Psychiatry, Monash University, Melbourne, Australia, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain and Red de Trastornos Adictivos, Universidad de Granada. Granada, Spain; Luke Clark, PhD, Department of Psychology, Centre for Gambling Research at UBC, University of British Columbia, Canada; Juan Verdejo-Román, MSc, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; Natalia Albein-Urios, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; José M. Martinez-Gonzalez, PhD, Red de Trastornos Adictivos, Universidad de Granada, Granada, Spain and Centro Provincial de Drogodependencias, Diputacion de Granada, Granada, Spain; Blanca Gutierrez, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain, Department of Psychiatry, Universidad de Granada, Granada, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain; Carles Soriano-Mas, PhD, Department of Psychiatry, Bellvitge Biomedical Research Institute-IDIBELL, Barcelona, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain, Department of Psychobiology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, Spain Antonio.Verdejo@monash.edu.
authors.forename: Antonio
authors.initials: A
authors.lastname: Verdejo-Garcia
authors.affiliation: Antonio Verdejo-Garcia, PhD, School of Psychology and Psychiatry, Monash University, Melbourne, Australia, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain and Red de Trastornos Adictivos, Universidad de Granada. Granada, Spain; Luke Clark, PhD, Department of Psychology, Centre for Gambling Research at UBC, University of British Columbia, Canada; Juan Verdejo-Román, MSc, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; Natalia Albein-Urios, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; José M. Martinez-Gonzalez, PhD, Red de Trastornos Adictivos, Universidad de Granada, Granada, Spain and Centro Provincial de Drogodependencias, Diputacion de Granada, Granada, Spain; Blanca Gutierrez, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain, Department of Psychiatry, Universidad de Granada, Granada, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain; Carles Soriano-Mas, PhD, Department of Psychiatry, Bellvitge Biomedical Research Institute-IDIBELL, Barcelona, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain, Department of Psychobiology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, Spain.
authors.forename: Luke
authors.initials: L
authors.lastname: Clark
authors.affiliation: Antonio Verdejo-Garcia, PhD, School of Psychology and Psychiatry, Monash University, Melbourne, Australia, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain and Red de Trastornos Adictivos, Universidad de Granada. Granada, Spain; Luke Clark, PhD, Department of Psychology, Centre for Gambling Research at UBC, University of British Columbia, Canada; Juan Verdejo-Román, MSc, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; Natalia Albein-Urios, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; José M. Martinez-Gonzalez, PhD, Red de Trastornos Adictivos, Universidad de Granada, Granada, Spain and Centro Provincial de Drogodependencias, Diputacion de Granada, Granada, Spain; Blanca Gutierrez, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain, Department of Psychiatry, Universidad de Granada, Granada, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain; Carles Soriano-Mas, PhD, Department of Psychiatry, Bellvitge Biomedical Research Institute-IDIBELL, Barcelona, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain, Department of Psychobiology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Verdejo-Román
authors.affiliation: Antonio Verdejo-Garcia, PhD, School of Psychology and Psychiatry, Monash University, Melbourne, Australia, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain and Red de Trastornos Adictivos, Universidad de Granada. Granada, Spain; Luke Clark, PhD, Department of Psychology, Centre for Gambling Research at UBC, University of British Columbia, Canada; Juan Verdejo-Román, MSc, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; Natalia Albein-Urios, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; José M. Martinez-Gonzalez, PhD, Red de Trastornos Adictivos, Universidad de Granada, Granada, Spain and Centro Provincial de Drogodependencias, Diputacion de Granada, Granada, Spain; Blanca Gutierrez, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain, Department of Psychiatry, Universidad de Granada, Granada, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain; Carles Soriano-Mas, PhD, Department of Psychiatry, Bellvitge Biomedical Research Institute-IDIBELL, Barcelona, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain, Department of Psychobiology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, Spain.
authors.forename: Natalia
authors.initials: N
authors.lastname: Albein-Urios
authors.affiliation: Antonio Verdejo-Garcia, PhD, School of Psychology and Psychiatry, Monash University, Melbourne, Australia, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain and Red de Trastornos Adictivos, Universidad de Granada. Granada, Spain; Luke Clark, PhD, Department of Psychology, Centre for Gambling Research at UBC, University of British Columbia, Canada; Juan Verdejo-Román, MSc, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; Natalia Albein-Urios, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; José M. Martinez-Gonzalez, PhD, Red de Trastornos Adictivos, Universidad de Granada, Granada, Spain and Centro Provincial de Drogodependencias, Diputacion de Granada, Granada, Spain; Blanca Gutierrez, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain, Department of Psychiatry, Universidad de Granada, Granada, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain; Carles Soriano-Mas, PhD, Department of Psychiatry, Bellvitge Biomedical Research Institute-IDIBELL, Barcelona, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain, Department of Psychobiology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, Spain.
authors.forename: José M
authors.initials: JM
authors.lastname: Martinez-Gonzalez
authors.affiliation: Antonio Verdejo-Garcia, PhD, School of Psychology and Psychiatry, Monash University, Melbourne, Australia, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain and Red de Trastornos Adictivos, Universidad de Granada. Granada, Spain; Luke Clark, PhD, Department of Psychology, Centre for Gambling Research at UBC, University of British Columbia, Canada; Juan Verdejo-Román, MSc, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; Natalia Albein-Urios, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; José M. Martinez-Gonzalez, PhD, Red de Trastornos Adictivos, Universidad de Granada, Granada, Spain and Centro Provincial de Drogodependencias, Diputacion de Granada, Granada, Spain; Blanca Gutierrez, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain, Department of Psychiatry, Universidad de Granada, Granada, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain; Carles Soriano-Mas, PhD, Department of Psychiatry, Bellvitge Biomedical Research Institute-IDIBELL, Barcelona, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain, Department of Psychobiology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, Spain.
authors.forename: Blanca
authors.initials: B
authors.lastname: Gutierrez
authors.affiliation: Antonio Verdejo-Garcia, PhD, School of Psychology and Psychiatry, Monash University, Melbourne, Australia, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain and Red de Trastornos Adictivos, Universidad de Granada. Granada, Spain; Luke Clark, PhD, Department of Psychology, Centre for Gambling Research at UBC, University of British Columbia, Canada; Juan Verdejo-Román, MSc, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; Natalia Albein-Urios, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain; José M. Martinez-Gonzalez, PhD, Red de Trastornos Adictivos, Universidad de Granada, Granada, Spain and Centro Provincial de Drogodependencias, Diputacion de Granada, Granada, Spain; Blanca Gutierrez, PhD, Institute of Neuroscience F. Oloriz, Universidad de Granada, Granada, Spain, Department of Psychiatry, Universidad de Granada, Granada, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain; Carles Soriano-Mas, PhD, Department of Psychiatry, Bellvitge Biomedical Research Institute-IDIBELL, Barcelona, Spain and CIBERSAM, Carlos III Health Institute, Barcelona, Spain, Department of Psychobiology and Methodology of Health Sciences, Universitat Autònoma de Barcelona, Spain.
authors.forename: Carles
authors.initials: C
authors.lastname: Soriano-Mas
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001921:Brain / Q000502:physiology*; D016022:Case-Control Studies; D019970:Cocaine-Related Disorders / Q000235:genetics / Q000503:physiopathology*; D003071:Cognition / Q000502:physiology*; D005260:Female; D005715:Gambling / Q000235:genetics / Q000503:physiopathology*; D005838:Genotype; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D011597:Psychomotor Performance / Q000502:physiology; D017448:Receptors, Dopamine D2 / Q000235:genetics; D055815:Young Adult
chemical_list: C581293:DRD2 protein, human; D017448:Receptors, Dopamine D2; C489948:ANKK1 protein, human; D017346:Protein Serine-Threonine Kinases